ArticleBMJ open2022

Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma.

Bo Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.